


AiCuris Initiates Clinical Development of AIC499, a Novel Resistance-Breaking Antibiotic against a Broad Range of MDR Gram-Negative Bacteria

CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant

Merck & Co., Inc – Partnering with Local Hospitals Worldwide to Implement Antimicrobial Stewardship (AMS) Programs
